About: Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://www.hindawi.com/crim/hematology/2012/369086/
Description	Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies are mandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoeconomy. Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies are mandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoeconomy. (en)
Title	Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports (en)
skos:prefLabel	Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports (en)
skos:notation	RIV/61989592:15110/12:33142581!RIV13-MZ0-15110___
http://linked.open...avai/predkladatel	Lékařská fakulta
http://linked.open...avai/riv/aktivita	I P S Z
http://linked.open...avai/riv/aktivity	I, P(NT12218), S, Z(MSM6198959205), Z(MSM6198959223)
http://linked.open...iv/cisloPeriodika	369086
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Vondráková, Jana INDRÁK, Karel Rohoň, Peter Jarošová, Marie Holzerová, Milena
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	175038
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/12:33142581
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	chronic myelomonocytic leukemia; allogenic stem cell transplantation (ASCT) (en)
http://linked.open.../riv/klicoveSlovo	allogenic stem cell transplantation (ASCT) chronic myelomonocytic leukemia
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[CB2AB4A1C58B]
http://linked.open...i/riv/nazevZdroje	Case Reports in Hematology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	5 (xsd:int)
http://linked.open...cetTvurcuVysledku	6 (xsd:int)
http://linked.open...vavai/riv/projekt	Personalized treatment of chronic myeloproliferative disorders and myelodysplastic syndrome - a cellular metabolomics study.
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	2012
http://linked.open...iv/tvurceVysledku	Indrák, Karel Jarošová, Marie Rohoň, Peter Vondráková, Jana Jonášová, Anna Holzerová, Milena
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment Nové možnosti diagnostiky a imunomodulace u infekčních onemocnění a imunopatologických stavů
issn	2090-6579
number of pages	4 (xsd:int)
http://bibframe.org/vocab/doi	10.1155/2012/369086
http://localhost/t...ganizacniJednotka	15110
is http://linked.open...avai/riv/vysledek of	Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software